Clinical Trials Directory

Trials / Completed

CompletedNCT01650181

Effects of Siliphos-Selenium-Methionine-Alpha Lipoic Acid in Patients With Fatty Liver and Non-alcoholic Steatohepatitis

Biochemical and Echosonographic Impacts Using Siliphos-Selenium-Methionine-Alpha Lipoic Acid + Metformin Versus Metformin in Patients With Fatty Liver and Steatohepatitis

Status
Completed
Phase
Phase 4
Study type
Interventional
Enrollment
50 (actual)
Sponsor
Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran · Academic / Other
Sex
All
Age
18 Years – 65 Years
Healthy volunteers
Not accepted

Summary

Non-alcoholic steatohepatitis represents 10 - 15% total cases of hepatic cirrhosis. In the upcoming years, the economic burden of this disease will increase and will mean an important problem for our health system due to obesity epidemic. There are several treatments for non-alcoholic steatohepatitis; however, none of them have overcome a healthy lifestyle including diet, exercise and some drugs related with insulin metabolism. There after, using hepatoprotective drugs and antioxidants have been recommended as an eligible therapy to reduce the progression from fatty liver to steatohepatitis and cirrhosis. Being this approach not only an experimental item yet but also an unavoidable reality. The purpose of this randomized controlled study is explore the effects of siliphos-selenium-methionine-alpha lipoic acid + metformin versus metformin in patients with fatty liver and non-alcoholic steatohepatitis about biochemical and echosonographic parameters.

Conditions

Interventions

TypeNameDescription
DRUGMetforminPatients with Steatohepatitis treated with diet, exercise and metformin
DIETARY_SUPPLEMENTSiliphos+ Selenium - Methionine + Alpha Lipoic AcidPatients with Steatohepatitis treated with diet, exercise, metformin and Siliphos (140mg) + Selenium (15 mcg) - Methionine (3mg) + Alpha Lipoic Acid (200mg), two tablets BID
DIETARY_SUPPLEMENTSiliphos+ Selenium - Methionine + Alpha Lipoic AcidPatients with fatty liver treated with diet, exercise, metformin and Siliphos (140mg) + Selenium (15 mcg) - Methionine (3mg) + Alpha Lipoic Acid (200mg), two tablets BID
DRUGMetforminPatients with fatty liver treated with diet, exercise and metformin

Timeline

Start date
2011-11-01
Primary completion
2014-03-01
Completion
2014-06-01
First posted
2012-07-26
Last updated
2014-08-20

Locations

1 site across 1 country: Mexico

Source: ClinicalTrials.gov record NCT01650181. Inclusion in this directory is not an endorsement.